Receipt of perioperative blood transfusion after surgery for renal cell carcinoma is associated with a higher risk of tumor recurrence, progression, and death. READ MORE
Quality of life in advanced renal cell carcinoma may be somewhat better for patients who receive nivolumab rather than everolimus.
Research in Review
A look at 14 years of health care trends has revealed that the percentage of patients receiving treatment for metastatic renal cell carcinoma (mRCC) is growing as providers shift toward targeted therapeutic approaches.